Primary cutaneous anaplastic large cell lymphoma
ICD-10 C86.6 · ICD-11 2B03.0&XH3400

Treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma Presenting with Solitary or Localised Tumours

This protocol covers the management of primary cutaneous anaplastic large cell lymphoma (PC-ALCL / C-ALCL) in patients who present with solitary or localised disease, including ulcerating tumours or nodules.

Clinical scenario: The patient has primary cutaneous ALCL presenting with solitary or localised (ulcerating) tumours or nodules — the characteristic pattern of C-ALCL at initial evaluation.
Treatment approach — partial overview

For a subset of patients in this setting, a multi-agent chemotherapy strategy is part of the treatment framework. The full structured regimen, including which patients qualify and the complete decision pathway, is available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

  1. Patients with C-ALCL generally present with solitary or localised (ulcerating) tumours or nodules and should be treated with RT or surgical excision (Figure 2).
  2. Multi-agent ChT is only indicated in patients presenting with or developing extracutaneous disease and in rare patients with rapidly progressive skin disease.
View source ↗